26 related articles for article (PubMed ID: 18084763)
21. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Am J Clin Oncol; 2011 Feb; 34(1):2-5. PubMed ID: 20042970
[TBL] [Abstract][Full Text] [Related]
22. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Schmittel A; Schuster R; Bechrakis NE; Siehl JM; Foerster MH; Thiel E; Keilholz U
Melanoma Res; 2005 Oct; 15(5):447-51. PubMed ID: 16179873
[TBL] [Abstract][Full Text] [Related]
23. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Keilholz U; Schuster R; Schmittel A; Bechrakis N; Siehl J; Foerster MH; Thiel E
Eur J Cancer; 2004 Sep; 40(14):2047-52. PubMed ID: 15341977
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):685-8. PubMed ID: 18084763
[TBL] [Abstract][Full Text] [Related]
25. Medical treatment of uveal melanoma.
Queirolo P; Acquati M
Tumori; 2007; 93(3):suppl 27-30. PubMed ID: 17679486
[No Abstract] [Full Text] [Related]
26.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
